AMG-386

trebananib · Amgen

Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for AMG-386, covering 2010-08-20 to 2026-03-12. Get the full timeline:

Most recent: Clinical Trial Update: Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor [Phase 1]